Group 1 - SeaStar Medical Holding Corporation announced a public offering of 6,153,847 shares of common stock at a price of $0.65 per share, with potential additional gross proceeds of up to $4 million from short-term warrants [1][4] - The Series A warrants will expire in five years, while the Series B short-term warrants will expire in 18 months, both having an exercise price of $0.65 per share [2] - The offering is expected to close around June 23, 2025, pending customary closing conditions [2] Group 2 - H.C. Wainwright & Co. is the exclusive placement agent for the offering [3] - The gross proceeds from the offering are anticipated to be approximately $4 million before deducting fees and expenses [4] - The net proceeds will be used for general corporate purposes [4] Group 3 - SeaStar Medical is focused on transforming treatments for critically ill patients facing organ failure, with its first product QUELIMMUNE approved by the FDA in 2024 for acute kidney injury in pediatric patients [7] - The company’s Selective Cytopheretic Device therapy has received Breakthrough Device Designation for six therapeutic indications, facilitating a faster approval process [7] - SeaStar is conducting a pivotal trial for its SCD therapy in adult patients with acute kidney injury, a condition affecting over 200,000 adults in the U.S. annually [7]

Core Insights - DexCom (DXCM) reported strong first-quarter 2025 results driven by high demand, record new patient growth, and progress in strategic initiatives [1] - The company’s shares have increased by 18.6% quarter to date, outperforming the industry’s decline of 4.5% [2] - DexCom has a market capitalization of $31.76 billion and projects a 23.1% growth rate over the next five years [2] Access Gain and Market Penetration - Significant expansion in reimbursement coverage for type 2 diabetes (T2D) patients, particularly non-insulin users, is expected to unlock access for nearly 6 million individuals [4] - The first quarter of 2025 saw a record increase in new patient starts from this cohort, the highest in DexCom's history [4] - The over-the-counter CGM, Stelo, is capturing a broader audience, including prediabetes patients and those interested in wellness [5][8] Innovation and Commercial Execution - The launch of the 15-Day G7 system is anticipated to enhance accuracy and product differentiation, potentially improving gross margins [10] - DexCom is optimizing its sales force and expanding its international presence, particularly in France and Japan [11] - The company has a strong cash position of $2.7 billion and announced a $750 million share buyback, indicating confidence in long-term cash flow [12] Estimate Trend - The Zacks Consensus Estimate for 2025 earnings per share remains stable at $2.03, with the second-quarter revenue estimate at $1.12 billion, reflecting an 11.8% year-over-year improvement [13][15] Navigating Near-Term Challenges - Gross margin guidance for fiscal 2025 has been revised down to nearly 62% due to supply-chain disruptions and increased freight costs [16] - DexCom is addressing an FDA warning letter from 2024 inspections, which requires ongoing resource allocation but does not restrict product approvals [17] - The company is advocating for Medicare coverage for non-insulin T2D users, contingent on a trial set to report results in late 2025 or early 2026 [18] CGM Competition on the Rise - DexCom faces increasing competition from Abbott Laboratories, Medtronic, and Senseonics, which are innovating rapidly in the CGM market [19] - Abbott's expansion with its FreeStyle Libre family and OTC devices directly challenges DexCom's Stelo strategy [20] - Medtronic's integration of CGM with insulin pumps and Senseonics' long-wear implantable CGM are also competitive threats [21][22]

Core Viewpoint - Aethlon Medical, Inc. is set to release its financial results for the fiscal fourth quarter ended March 31, 2025, on June 26, 2025, at 4:15 p.m. ET [1] Financial Results Announcement - The financial results will be followed by a conference call hosted by management on June 26, 2025, at 4:30 p.m. ET to discuss the results and recent corporate developments [2] - Interested parties can register for the conference call online, and registered participants will receive their dial-in number upon registration [2] Conference Call Details - For those without internet access, a toll-free participant dial-in number is available at 1-844-836-8741, with an international dial-in option at 1-412-317-5442 [3] - A replay of the call will be accessible approximately one hour after the call ends and will be available until July 26, 2025 [4] Company Overview - Aethlon Medical focuses on developing the Hemopurifier, an immunotherapeutic device aimed at treating cancer and life-threatening viral infections [5] - The Hemopurifier has shown promise in human studies for removing life-threatening viruses and harmful exosomes, which may contribute to immune suppression and cancer metastasis [5] - The device has received FDA Breakthrough Device designation for treating advanced or metastatic cancer and life-threatening viruses not addressed by approved therapies [5]

Company Overview - Align Technology (NASDAQ: ALGN) is recognized as a market leader in the digital dentistry platform sector, yet it is still valued by the market similarly to traditional orthodontic device companies [1] Market Opportunity - There exists a significant opportunity for Align Technology in underpenetrated scanner bases and the development of emerging recurring revenue streams [1] Market Sentiment - The current market sentiment remains pessimistic regarding Align Technology, despite the potential for growth and innovation within the company [1]

Zacks Investment Research has recently initiated coverage of Retractable Technologies, Inc. (RVP) , assigning an "Underperform" recommendation to the company's shares. This bearish stance reflects significant concerns over the company’s recent financial performance and operational challenges.Retractable Technologies, based in Little Elm, TX, manufactures and markets safety medical products, predominantly syringes and needles, for the healthcare industry. Its offerings are primarily aimed at reducing needles ...

Core Viewpoint - Intuitive Surgical has demonstrated impressive stock performance in the healthcare sector, driven by innovative robotics-assisted surgical devices that have garnered significant demand from medical professionals globally [1]. Company Performance - As of June 17, Intuitive Surgical's stock price is $509.49, with a P/E ratio of 74.71 and a price target of $588.95, indicating a potential upside of 15.60% [2][8]. - The stock has achieved a return of nearly 167% over the past three years, significantly outperforming the S&P 500 Index, which returned approximately 70% during the same period [2]. Analyst Opinions - Analysts are divided on the stock's valuation; Deutsche Bank's price target of $440 suggests a 14% downside, while Citigroup's target of $650 indicates a 27% upside [3]. - The consensus rating for Intuitive Surgical is a Moderate Buy, based on 20 analyst ratings [8][12]. Market Challenges - Tariffs are expected to negatively impact gross margins by 1.7% in 2025, with the company unable to mitigate these effects in the short term [3][4]. - Increased competition is emerging, particularly from Medtronic's Hugo system, which has already received regulatory clearance and shows a high surgical success rate [5][6]. Growth Potential - Approximately 58% of Intuitive's 10,189 Da Vinci systems are located in the U.S., indicating significant growth opportunities in international markets [4]. - The company believes it is "less than one-third penetrated" in its current markets, suggesting ample room for expansion as robotic-assisted surgeries are not yet widely adopted [8][9]. Competitive Advantages - Intuitive Surgical benefits from a two-decade head start over competitors, providing a scale advantage and established trust with healthcare providers [7]. - Despite the high forward P/E multiple of around 63x, this is justified given the company's dominant market position and growth potential [10].

This presentation contains financial forecasts with respect to the Company's projected financial results for the Company for the periods indicated. These projections should not be relied upon as being necessarily indicative of future results. The assumptions and estimates underlying the prospective financial information are inherently uncertain and are subject to a wide variety of significant business, economic and competitive risks and uncertainties that could cause actual results to differ materially from ...

NASDAQ: LUNG February 2025 © 2025 Pulmonx Corporation 1 Forward Looking Statement This presentation and certain statements made during this presentation contain forward-looking statements that involve risks and uncertainties. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business ...

Investor Day Welcome Investors' Day Agenda Welcome; Logistics; Agenda Raj Denhoy Corporate Overview Peter Caldini Motiva® USA Business Updates Jeff Ehrhardt US Breast Aesthetic - Panel Ben Newcott Breast Reconstruction Opportunity in the USA Jeff Ehrhardt US Breast Reconstruction - Panel Ben Newcott Unlocking New Markets - Panel Juan José Chacón-Quirós Management Q&A Topic Presenter/Moderator Innovation Pipeline Roberto de Mezerville GLP-1s and Plastic Surgery Juan José Chacón-Quirós Agenda Forward Looking ...

Key Takeaways GE HealthCare launched the bkActiv S Series for image-guided, non-surgical urology and pelvic procedures. GEHC's bkActiv S Series offers AI tools, TruSense tech, and single-handed controls for clinician efficiency. GEHC aims to grow recurring revenue through transducer sales, service contracts, and software upgrades.GE HealthCare Technologies Inc. (GEHC) recently expanded its bkPortfolio family of Active Imaging systems with the launch of the bkActiv S Series, a next-generation ultrasound so ...